Aranesp (darbepoetin alfa)
Aranesp is an erythropoiesis-stimulating drug used for the treatment of patients with anemia associated with myelosuppressive chemotherapy.
Amgen offers 1 financial assistance program for patients using Aranesp:
Amgen Safety Net Foundation
Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Aranesp for free through this nonprofit program from Amgen.
Injectafer (ferric carboxymaltose injection)
Injectafer is an iron replacement drug used for the treatment of adults with anemia caused by iron deficiency in patients with cancer.
Daiichi-Sankyo offers 2 financial assistance programs for patients who have been prescribed Injectafer:
Injectafer Savings Program
Through this program, qualifying patients with private insurance will pay the first $50 for the first dose of Injectafer and then pay as little as $0 for the second dose. Patients can receive up to $500 in assistance for each dose of Injectafer, with a maximum benefit of $1,000 for every 2 doses.
Injectafer Patient Assistance Program
Patients who are uninsured and are not eligible for public (government) assistance may qualify to receive Injectafer for free if they meet certain income criteria.
Retacrit (epoetin alfa-epbx)
Retacrit, a biosimilar to Epogen and Procrit, is an erythropoiesis- stimulating agent used for the treatment of anemia associated with concomitant myelosuppressive chemotherapy in patients with non-myeloid cancer who need at least 2 additional months of chemotherapy.
Pfizer Oncology Together offers 1 financial assistance program for patients who have been prescribed Retacrit:
Pfizer Patient Assistance Program
Through this program, patients who are underinsured or uninsured may qualify to receive Retacrit for free or at a savings. Eligible patients who have government insurance may also be able to receive Retacrit for free if they cannot find support from an independent charitable foundation.
Prolia (denosumab) Injection
Prolia is a RANK ligand inhibitor used to increase bone mass in adults at high risk for fracture, specifically men who receive androgen-deprivation therapy for non-metastatic prostate cancer and women who receive adjuvant aromatase inhibitor therapy for breast cancer.
Amgen has 2 financial assistance programs available for patients using Prolia:
Amgen FIRST STEP Program
For privately insured patients whose insurance covers Prolia, this program provides a copay of $0 for the first dose and $25 for each dose thereafter, with a maximum benefit of $1,500 per patient per calendar year.
Amgen Safety Net Foundation
Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Prolia for free through this nonprofit program from Amgen.
Xgeva (denosumab)
Xgeva is a RANK ligand inhibitor used for the prevention of skeletal-related events in patients with bone metastases from solid tumors, as well as for the treatment of patients with giant-cell tumor of the bone.
Amgen offers 2 financial assistance programs for patients using Xgeva:
Amgen FIRST STEP Program
For privately insured patients whose insurance covers Xgeva, this program ensures a copay of $0 for the first dose, and then $5 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.
Amgen Safety Net Foundation
Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Xgeva for free through this nonprofit program from Amgen.
Lazanda (fentanyl)
Lazanda is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.
West Therapeutic Development offers 1 financial assistance program for patients using Lazanda:
Lazanda Savings Card
Patients with private insurance are eligible for this prescription savings card. With the card, eligible patients will pay a copay of $25 for a prescription of Lazanda, with a maximum benefit of up to $14,000, and a maximum of 30 bottles per 30 days.
Subsys (fentanyl sublingual spray)
Subsys is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.
West Therapeutic Development offers 1 financial assistance program for patients using Subsys:
Subsys Copay Savings Program
Privately insured and uninsured patients can use this copay savings card to receive 10 free units of 100-mcg Subsys and/or up to 30 free units of 100 mcg to 1,600 mcg of Subsys. Patients will also receive up to $4,000 off each additional prescription of Subsys.
Akynzeo (netupitant + palonosetron)
Akynzeo is a fixed combination of netupitant and palonosetron used, in combination with dexamethasone, for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.
Helsinn Cares offers 2 financial assistance programs for patients using Akynzeo:
Akynzeo Capsule Savings Card
Privately insured patients will benefit from this program. Helsinn will pay up to $150 copay savings per Akynzeo capsule prescription.
Helsinn Cares Patient Assistance Program
This program provides Akynzeo at no cost to patients with financial needs who meet the program’s eligibility criteria.
Emend (aprepitant)
Emend is a substance P/neurokinin-1 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy in pediatric and adult patients with cancer. Emend is also used to prevent postoperative nausea and vomiting in adults.
Merck offers 1 financial assistance program for patients using Emend:
Merck Patient Assistance Program
Patients without insurance or prescription coverage may be eligible to receive Emend for free. Eligible patients must have an annual household income of $51,040 or less for individuals, $68,960 or less for couples, or $104,800 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have difficulty paying for medicines may request that an exception be made, provided their annual household income is not more than a set limit.
Sancuso (granisetron transdermal system)
Sancuso is a serotonin-3 receptor antagonist used to prevent nausea and vomiting in patients receiving chemotherapy for up to 5 consecutive days.
Kyowa Kirin offers 2 financial assistance programs for patients using Sancuso:
Sancuso Copay Assistance Card Program
Insured patients can use the Sancuso Copay Assistance Card for up to 48 patches per patient, with a maximum of 4 patches and a $1,200 benefit monthly. With the card, patients will pay the initial $20 of their copay and any remaining outof- pocket costs will be reduced by up to $300 monthly.
Sancuso Patient Assistance Program
Patients who do not have insurance and who do have an income at or below 300% of the current federal poverty level are eligible to receive free Sancuso.
Sustol (granisetron)
Sustol is a serotonin-3 receptor antagonist used, in combination with antiemetic agents, to prevent acute and delayed nausea and vomiting associated with chemotherapy.
Sustol Connect Patient Services offers 2 financial assistance programs for patients using Sustol:
Heron Connect Copay Assistance Program
Patients with private or commercial insurance can benefit from $0 out-of-pocket costs for Sustol through the availability of this copay assistance program from Heron Therapeutics.
Heron Connect Patient Assistance Program
Sustol can be provided at no cost to patients with financial hardship who meet the program eligibility criteria.
Varubi (rolapitant)
Varubi is a substance P/neurokinin-1 receptor antagonist used, in combination with other antiemetic drugs, to prevent delayed nausea and vomiting in patients with cancer who are receiving chemotherapy.
TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Varubi:
Varubi Co-Pay Card
Eligible patients who have private insurance may pay as little as $0 for their prescription of Varubi, with a maximum benefit of $2,000 per year.
Actemra (tocilizumab)
Actemra is an interleukin-6 receptor antagonist used for the treatment of adults and pediatric patients age 2 or older who have CAR T-cell-induced, severe or life-threatening cytokine-release syndrome.
Genentech Oncology offers 2 financial assistance programs for patients using Actemra:
Actemra Co-pay Card Program
This program helps eligible, privately insured patients, who have been prescribed Actemra for any approved indication, to pay just $5 per drug copay. The card is valid for up to $15,000 in assistance within a 12-month period.
Genentech Patient Foundation
This foundation provides Actemra free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Actemra is also provided free for patients who are unable to afford their out-ofpocket costs and cannot find other financial assistance.
Imbruvica (ibrutinib) Capsules/Tablets
Imbruvica is a Bruton tyrosine kinase inhibitor used for the treatment of patients with graft-versus-host disease, after failure of 1 or more systemic therapies.
The You&I Support Program offers 2 financial assistance programs for patients who are prescribed Imbruvica:
You&I Instant Savings Program
Patients with commercial or private insurance will pay no more than $10 monthly for Imbruvica. Eligible patients may qualify for instant savings on their commercial insurance copay, deductible, and co-insurance medication costs for Imbruvica.
Johnson & Johnson Patient Assistance Foundation
This program provides Imbruvica free of charge to patients who meet certain financial limits and are uninsured, underinsured, or enrolled in Medicare Part D.
Jakafi (ruxolitinib)
Jakafi is a kinase inhibitor used for the treatment of patients aged 12 years or older with steroid-refractory acute graft-versus- host disease (GVHD). GVHD can occur after a bone marrow transplant (allogeneic stem-cell transplant) in patients with different types of blood cancer, including leukemia, lymphoma, or multiple myeloma.
Incyte offers 3 financial assistance programs for patients who are prescribed Jakafi:
IncyteCARES Copay/Coinsurance Program
Patients with commercial or private insurance who are eligible to receive Jakafi will pay only $0 monthly. The amount of savings will not exceed $11,977 monthly and $25,000 annually.
To enroll in this program, patients must call IncyteCARES (855-452-5234) to determine eligibility; a membership number is provided immediately, and a copay/co-insurance card is activated for eligible patients. To receive copay assistance, patients must contact the specialty pharmacy and provide copay information so that they can apply the copay amount toward the prescription. Eligible patients experiencing an insurance coverage delay can receive a free supply of Jakafi.
IncyteCARES Patient Assistance Program
Patients without prescription drug coverage for Jakafi, or those whose insurance has denied claims, may be eligible to receive the drug free of charge through this program. To enroll in this program, patients must reside in the United States or Puerto Rico, have an annual household income of less than $125,000 or 600% of the federal poverty level, whichever is greater, and have a valid prescription for an FDAapproved indication.
Patients and their providers must complete the enrollment form and fax it to 855-525-7207 or mail it directly to the address listed on the form.
IncyteCARES Temporary Access Program
Eligible patients who experience a delay in insurance coverage may be able to receive a free 30-day supply of Jakafi. Patients must have private or commercial coverage to qualify for this program.
Fulphila (pegfilgrastim-jmdb)
Fulphila, a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the risk of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.
Mylan Advocate offers 2 financial assistance programs for patients who have been prescribed Fulphila:
Mylan Advocate Co-Pay Assistance Program
For patients who have private insurance and meet eligibility criteria, this program will pay the full amount of the patient’s out-of-pocket cost of Fulphila, with a maximum benefit of $10,000 per 12 months.
Mylan Advocate Patient Assistance
Uninsured patients who cannot afford their medication may be eligible to receive Fulphila free of charge. Eligibility requirements include US residency, income level, and other factors.
Neulasta (pegfilgrastim)
Neulasta is a leukocyte growth factor used to decrease the incidence of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.
Amgen offers 2 financial assistance programs for patients using Neulasta:
Amgen FIRST STEP Program
For privately insured patients whose insurance covers Neulasta, this program ensures a copay of $0 for the first dose, and $5 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.
Amgen Safety Net Foundation
Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neulasta for free through this nonprofit program from Amgen.
Neupogen (filgrastim)
Neupogen is a leukocyte growth factor used to decrease infections associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy. Neupogen is also used for the treatment of neutropenia in patients with cancer.
Amgen offers 2 financial assistance programs for patients using Neupogen:
Amgen FIRST STEP Program
For privately insured patients whose insurance covers Neupogen, this program ensures a copay of $0 for the first dose, and $5 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.
Amgen Safety Net Foundation
Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neupogen for free through this nonprofit program from Amgen.
Nivestym (filgrastim-aafi) Injection
Nivestym, a biosimilar to Neupogen, is a leukocyte growth factor used to decrease infections associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy. For patients with acute myeloid leukemia (AML) who received induction or consolidation chemotherapy, Nivestym reduces neutrophil recovery time and duration of fevers. For patients who received a bone marrow transplant after chemotherapy, Nivestym reduces the duration of neutropenia and neutropenia-related conditions. Nivestym is also used to manage conditions related to severe neutropenia in patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia; and for patients who require autologous peripheral blood progenitor-cell collection and therapy.
Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Nivestym:
Pfizer Oncology Together Co-Pay Assistance Program
Through this program, eligible patients who have private insurance may pay $0 for Nivestym, with a maximum benefit of $10,000 per year.
Pfizer Patient Assistance Program
This program serves patients who are either uninsured or those with government insurance. Uninsured patients who qualify may receive Nivestym for free or at a savings. Patients with government insurance who cannot find independent charitable support may qualify to receive Nivestym for free.
Udenyca (pegfilgrastim-cbqv)
Udenyca, a biosimilar to Neulasta, is a leukocyte growth factor used to decrease the risk of infection associated with febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy.
Coherus COMPLETE offers 2 financial assistance programs for patients who have been prescribed Udenyca:
Coherus COMPLETE Co-Pay Assistance Program
This program reduces the patient’s out-of-pocket costs of Udenyca for patients who have commercial insurance. The out-of-pocket cost for eligible patients is $0 per dose of Udenyca, with a maximum annual benefit of $15,000 per 12-month enrollment period.
Coherus COMPLETE Patient Assistance Program
Patients who are uninsured or underinsured and have financial hardship may receive Udenyca at no cost for 1 year through this program.
Zarxio (filgrastim-sndz)
Zarxio, a biosimilar to Neupogen, is a leukocyte growth factor used to decrease the risk of infection associated with febrile neutropenia in patients with cancer. Zarxio is also used for the treatment of neutropenia in patients with cancer.
Sandoz offers 1 financial assistance program for patients using Zarxio:
Sandoz One Source Commercial Co-Pay Program
Through this program, privately insured patients will pay $0 for the first dose of Zarxio and $0 for subsequent doses, with a maximum benefit of $10,000 annually. There is no income eligibility requirement.
Ziextenzo (pegfilgrastim-bmez)
Ziextenzo (pegfilgrastim-bmez), a biosimilar to Neulasta, is a leukocyte growth factor used to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid cancers who are receiving myelosuppressive chemotherapy drugs.
Sandoz provides 1 financial assistance program for patients who have been prescribed Ziextenzo:
Sandoz One Commercial Co-Pay Program
Through this program, patients who have private insurance will pay $0 for the first dose of Ziextenzo, and $0 for subsequent doses, with a maximum benefit of $10,000 annually. This program has no income requirements.
Table. Drugs Prescribed for Side‑Effects Management (Supportive Care)
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Aranesp (darbepoetin alfa)
- Amgen
- Treatment of anemia associated with myelosuppressive chemotherapy
- Amgen Safety Net Foundation
888-762-6436
- Injectafer (ferric carboxymaltose injection)
- Daiichi-Sankyo
- Treatment of anemia in patients with cancer
- Injectafer Savings Program
866-437-4669
Injectafer Patient Assistance Program
- Retacrit (epoetin alfa-epbx)
- Pfizer
- Treatment of anemia associated with myelosuppressive chemotherapy
- Pfizer Patient Assistance Program
877-744-5675
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Prolia (denosumab) Injection
- Amgen
- To increase bone mass in high-risk men receiving androgen-deprivation therapy for non-metastatic prostate cancer, and in women receiving adjuvant aromatase inhibitor therapy for breast cancer
- Amgen FIRST STEP Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436
- Xgeva (denosumab)
- Amgen
- Treatment of bone metastases
- Amgen FIRST STEP Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Lazanda (fentanyl)
- West Therapeutic Development
- Treatment of breakthrough cancer pain
- Lazanda Savings Card
844-309-3835
- Subsys (fentanyl sublingual spray)
- West Therapeutic Development
- Treatment of breakthrough cancer pain
- Subsys Copay Savings Program
855-766-6502
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Akynzeo (netupitant + palonosetron)
- Helsinn
- Prevention of chemotherapy-induced nausea and vomiting, in combination with dexamethasone
- Akynzeo Capsule Savings Card
844-357-4668
Helsinn Cares Patient Assistance Program
844-357-4668
- Emend (aprepitant)
- Merck
- Chemotherapy-induced
nausea and
vomiting
Postoperative nausea and vomiting - Merck Patient Assistance Program
855-257-3932
- Sancuso (granisetron transdermal system)
- Kyowa Kirin
- Prevent chemotherapyinduced nausea and vomiting
- Sancuso Copay Assistance Card Program
877-251-4951
Sancuso Patient Assistance Program
866-325-8231
- Sustol (granisetron)
- Heron Therapeutics
- Prevent chemotherapy-induced nausea and vomiting, in combination with other drugs
- Heron Connect Copay
Assistance Program
844-437-6611
Heron Connect Patient Assistance Program
844-437-6611
- Varubi (rolapitant)
- TerSera Therapeutics
- Prevent chemotherapyinduced nausea and vomiting, in combination with other antiemetic drugs
- Varubi Co-Pay Card
844-864-3014
Varubi Patient Assistance Program
855-686-8725
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Actemra (tocilizumab)
- Genentech
- Treatment of cytokine-release syndrome caused by CAR T-cell therapy
- Actemra Co-pay Card Program
855-722-6729
Genentech Patient Foundation
888-941-3331
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Imbruvica (ibrutinib) Capsules/Tablets
- Pharmacyclics
- Treatment of patients with graftversus-host disease, after failure of 1 or more systemic therapies
- You&I Instant Savings
Program
877-877-3536
Johnson & Johnson Patient Assistance Foundation
800-652-6227
- Jakafi (ruxolitinib)
- Incyte
- Treatment of steroid- refractory acute graft-versushost disease, in patients aged 12 or older
- IncyteCARES Copay/Coinsurance
Program
855-452-5234
IncyteCARES Patient Assistance Program
855-452-5234
IncyteCARES Temporary Access Program
855-452-5234
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Fulphila (pegfilgrastim-jmdb)
- Mylan
- To prevent febrile neutropenia associated with myelosuppressive chemotherapy
- Mylan Advocate Co-Pay Assistance Program
833-695-2623
Mylan Advocate Patient Assistance Program
833-695-2623
- Neulasta (pegfilgrastim)
- Amgen
- To prevent febrile neutropenia associated with myelosuppressive chemotherapy
- Amgen FIRST STEP Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436
- Neupogen (filgrastim)
- Amgen
- To prevent febrile
neutropenia
associated with
myelosuppressive
chemotherapy
Treatment of neutropenia - Amgen FIRST STEP
Program
888-657-8371
Amgen Safety Net Foundation
888-762-6436
- Nivestym (filgrastim-aafi) Injection
- Pfizer
- To prevent febrile neutropenia associated with myelosuppressive chemotherapy
- Pfizer Oncology Together Co-Pay Assistance Program
877-744-5675
Pfizer Patient Assistance Program
877-744-5675
- Udenyca (pegfilgrastim-cbqv)
- Coherus BioSciences
- To prevent febrile neutropenia associated with myelosuppressive chemotherapy
- Coherus COMPLETE Co-Pay Assistance Program
844-483-3692
Coherus COMPLETE Patient Assistance Program
844-483-3692
- Zarxio (filgrastim-sndz)
- Sandoz
- To prevent febrile
neutropenia
associated with
myelosuppressive
chemotherapy
Treatment of neutropenia - Sandoz One Source Commercial Co-Pay Program
844-726-3691
- Ziextenzo (pegfilgrastim-bmez)
- Sandoz
- To prevent febrile neutropenia associated with myelosuppressive chemotherapy
- Sandoz One Source Commercial Co-Pay Program
